HAEMONETICS CORP/MASS (HAE) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:HAE - US4050241003 - Common Stock
HAE Key Statistics, Chart & Performance
The current stock price of HAE is 66.06 USD. In the past month the price decreased by -17.97%. In the past year, price decreased by -4.33%.
HAE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HAE. When comparing the yearly performance of all stocks, HAE is one of the better performing stocks in the market, outperforming 74.85% of all stocks.
HAE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HAE. HAE has an excellent profitability rating, but there are some minor concerns on its financial health.
HAE Financial Highlights
Over the last trailing twelve months HAE reported a non-GAAP Earnings per Share(EPS) of 4.8. The EPS increased by 17.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.67% | ||
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| Debt/Equity | 1.08 |
HAE Forecast & Estimates
15 analysts have analysed HAE and the average price target is 93.84 USD. This implies a price increase of 42.05% is expected in the next year compared to the current price of 66.06.
For the next year, analysts expect an EPS growth of 8.59% and a revenue growth -3.06% for HAE
HAE Ownership
About HAE
Company Profile
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.
Company Info
HAEMONETICS CORP/MASS
125 Summer Street
Boston MASSACHUSETTS 02110 US
CEO: Christopher A. Simon
Employees: 3657
Phone: 17818487100
HAEMONETICS CORP/MASS / HAE FAQ
What does HAEMONETICS CORP/MASS do?
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.
Can you provide the latest stock price for HAEMONETICS CORP/MASS?
The current stock price of HAE is 66.06 USD. The price decreased by -2.67% in the last trading session.
Does HAE stock pay dividends?
HAE does not pay a dividend.
What is the ChartMill technical and fundamental rating of HAE stock?
HAE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of HAEMONETICS CORP/MASS (HAE) based on its PE ratio?
The PE ratio for HAEMONETICS CORP/MASS (HAE) is 13.76. This is based on the reported non-GAAP earnings per share of 4.8 and the current share price of 66.06 USD.
How many employees does HAEMONETICS CORP/MASS have?
HAEMONETICS CORP/MASS (HAE) currently has 3657 employees.
What is the next earnings date for HAE stock?
HAEMONETICS CORP/MASS (HAE) will report earnings on 2026-02-05, before the market open.